UNSPSC 51361930: Barbital sodium

This classification denotes a barbiturate with the molecular formula C8H11N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 275L5M93QS, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl-, monosodium salt (9ci) but more generally known as barbital sodium, which bears US NIH Compound Identifier 8943. European Medicines Agency schedules Barbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06103MIG.

UNSPSC 51361930 Barbital sodium is a Commodity code representing pharmaceutical active ingredients and finished pharmaceutical products that state and local health agencies purchase for clinical and emergency response programs. Recent state and local solicitations show that public health departments, county health systems, and state benefit programs are acquiring naloxone, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles. The work involves procuring pharmaceutical products with specific regulatory compliance requirements, including FDA registration, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and proof of legal authorization to distribute controlled or regulated substances in the United States. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances administering contracts on behalf of multiple participating jurisdictions and government facilities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due July 26, 2023 (note: date anomaly in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. Vendors must be prepared to supply through authorized wholesalers, maintain minimum insurance coverage including commercial general liability of $5,000,000 per occurrence, comply with pricing and administrative fee requirements, and meet specific onboarding and performance deadlines.